secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001847367-25-000026
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis Q1 net loss $99M, revenue $17.4M; merger with ACELYRIN on track for Q2 2025 close
--------------------------------------------------------------------------------

- Net loss of $99M in Q1 2025 vs $49.8M in Q1 2024; revenue of $17.4M from Kaken license fee.
- Cash and marketable securities $208.7M as of March 31, 2025; combined pro forma cash $737M with ACELYRIN.
- Merger with ACELYRIN approved by Alumis stockholders; exchange ratio 0.4814; expected close in Q2 2025.
- ESK-001 Phase 3 psoriasis topline data expected early Q1 2026; SLE Phase 2b data in 2026.
- R&D expenses $96.6M (up 130% YoY) driven by Phase 3 ONWARD program acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000184736725000026/0001847367-25-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000184736725000026/alms-20250514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001847367-25-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer